Identification of the Stapled α-Helical Peptide ATSP-7041 as a Substrate and Strong Inhibitor of OATP1B1 In Vitro
Biomolecules · 2023
DOI: 10.3390/biom13061002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2023. Verfasst von Rika Ishikawa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Safety Science, National Institute of Health Sciences, Kawasaki 210-9501, Japan. Hauptthemen laut MEDLINE: Neoplasm Proteins, Organic Anion Transporters. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
ATSP-7041, a stapled α-helical peptide that inhibits murine double minute-2 (MDM2) and MDMX activities, is a promising modality targeting protein–protein interactions. As peptides of molecular weights over 1000 Da are not usually evaluated, data on the drug–drug interaction (DDI) potential of stapled α-helical peptides remain scarce. Here, we evaluate the interaction of ATSP-7041 with hepatic cytochrome P450s (CYPs; CYP1A2, CYP2C9, CYP2C19, CYP3A4, and CYP2D6) and transporters (organic anion transporting polypeptides (OATPs; OATP1B1 and OATP1B3), P-glycoprotein (P-gp), and breast cancer resistance protein (BCRP)). ATSP-7041 demonstrated negligible metabolism in human liver S9 fraction and a limited inhibition of CYP activities in yeast microsomes or S9 fractions. On the contrary, a substantial uptake by OATPs in HEK 293 cells, a strong inhibition of OATP activities in the cells, and an inhibition of P-gp and BCRP activities in reversed membrane vesicles were observed for ATSP-7041. A recent report describes that ALRN-6924, an ATSP-7041 analog, inhibited OATP activities in vivo; therefore, we focused on the interaction between ATSP-7041 and OATP1B1 to demonstrate that ATSP-7041, as a higher molecular weight stapled peptide, is a substrate and strong inhibitor of OATP1B1 activity. Our findings demonstrated the possibility of transporter-mediated DDI potential by high molecular weight stapled peptides and the necessity of their evaluation for drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Safety Science, National Institute of Health Sciences, Kawasaki 210-9501, Japan.
- Division of Organic Chemistry, National Institute of Health Sciences, Kawasaki 210-9501, Japan.
ORCID-Profile: Kosuke Saito, Yosuke Demizu
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Ishikawa, R., Saito, K., Misawa, T., Demizu, Y., & Saito, Y. (2023). Identification of the Stapled α-Helical Peptide ATSP-7041 as a Substrate and Strong Inhibitor of OATP1B1 In Vitro. Biomolecules. https://doi.org/10.3390/biom13061002
Vancouver
Ishikawa R, Saito K, Misawa T, Demizu Y, Saito Y. Identification of the Stapled α-Helical Peptide ATSP-7041 as a Substrate and Strong Inhibitor of OATP1B1 In Vitro. Biomolecules. 2023. doi:10.3390/biom13061002
BibTeX
@article{Ishikawa2023,
author = {Ishikawa, Rika and Saito, Kosuke and Misawa, Takashi and Demizu, Yosuke and Saito, Yoshiro},
title = {Identification of the Stapled α-Helical Peptide ATSP-7041 as a Substrate and Strong Inhibitor of OATP1B1 In Vitro},
journal = {Biomolecules},
year = {2023},
doi = {10.3390/biom13061002}
}
EUVIMED